Chronic Cervical Myofascial Pain Syndrome (CMPS) is a persistent condition characterized by muscle pain and stiffness in the cervical region, often caused by muscle trigger points and soft tissue inflammation. It affects a significant portion of the adult population, leading to reduced quality of life and increased dependence on analgesics. Traditional management strategies include pharmacological treatments, physical therapy, and invasive procedures, but their effectiveness can be limited or accompanied by side effects. Recently, collagen mesotherapy has emerged as a promising therapeutic option, focusing on the regeneration and repair of connective tissue to alleviate pain symptoms.

Collagen mesotherapy involves the injection of collagen and other bioactive substances directly into affected tissues to promote healing and reduce inflammation. This technique aims to restore the structural integrity of connective tissues and enhance local blood circulation, thereby reducing pain and improving mobility. Given its minimally invasive nature and the potential for long-lasting benefits, collagen mesotherapy has gained attention within pain management and aesthetic medicine fields.

Understanding the pathophysiology of CMPS and the mechanisms by which collagen mesotherapy operates is essential for clinicians seeking alternative or adjunctive treatment modalities. This article comprehensively reviews the clinical evaluation of collagen mesotherapy's efficacy and safety in managing CMPS, emphasizing its therapeutic potential and implications for future pain management protocols.

The primary goal of this study is to assess the therapeutic efficacy and safety profile of collagen mesotherapy in patients diagnosed with chronic cervical myofascial pain syndrome. Pain intensity, functional improvement, and reduction in analgesic consumption serve as critical outcome measures to determine the treatment's clinical value. By evaluating these parameters, the study aims to provide evidence-based recommendations for incorporating collagen mesotherapy into standard CMPS care.

Moreover, assessing patient tolerance and monitoring adverse events are crucial components of this evaluation to establish the treatment’s safety for broader clinical application. Given the increasing interest in minimally invasive and regenerative therapies, this investigation contributes to filling knowledge gaps and guiding future clinical protocols.

The study also explores secondary benefits such as improved tissue elasticity and patient satisfaction, which are relevant for holistic CMPS management. These insights could inform integrative strategies combining collagen mesotherapy with conventional therapies to optimize patient outcomes.

This clinical evaluation employed a prospective, controlled study design involving patients diagnosed with chronic cervical myofascial pain syndrome according to established clinical criteria. Inclusion criteria encompassed adult patients experiencing persistent cervical pain for more than three months, with identifiable myofascial trigger points. Exclusion criteria included systemic inflammatory diseases, recent cervical trauma, and contraindications to mesotherapy.

Collagen mesotherapy was administered through multiple intramuscular injections targeting affected cervical muscles under aseptic conditions. The injected solution primarily contained type I collagen combined with supportive agents that enhance tissue regeneration and analgesic effects. Treatment sessions were conducted weekly for a total of six consecutive weeks.

Pain intensity was measured using the Visual Analog Scale (VAS) at baseline and subsequent follow-ups at 1, 3, and 6 months post-treatment. Concurrently, analgesic medication usage was documented to assess reductions in pharmacological dependency. Safety assessments included monitoring for local reactions, infection, or systemic adverse events throughout the study period.

The study enrolled 60 patients with a mean age of 45 years, comprising 65% females and 35% males. Baseline pain scores averaged 7.8 on the VAS, indicating moderate to severe pain intensity. Following collagen mesotherapy treatment, a statistically significant reduction in pain scores was observed at all follow-up intervals, with mean VAS scores decreasing to 3.2 at 6 months.

Additionally, 78% of patients reported a decrease in the frequency and dosage of analgesic medication, suggesting improved pain control and functional capacity. No serious adverse events were reported, with only minor transient reactions such as mild swelling or redness at injection sites in a minority of participants. These findings underscore the potential of collagen mesotherapy as a safe and effective intervention for CMPS.

Patient-reported outcomes indicated enhanced quality of life and satisfaction with treatment, supporting its role in comprehensive pain management strategies. The results highlight collagen mesotherapy’s ability to address both symptomatic relief and underlying tissue pathology.

The significant pain reduction and decreased reliance on analgesics observed in this study suggest that collagen mesotherapy effectively targets the musculoskeletal components of CMPS. By promoting collagen synthesis and connective tissue repair, this treatment may address the root causes of myofascial pain rather than merely mitigating symptoms. These clinical benefits align with the growing trend toward regenerative pain therapies that offer sustained relief with fewer side effects.

However, the study's limitations include a relatively small sample size and the absence of a placebo-controlled group, which may affect generalizability. Long-term efficacy beyond six months remains to be established through extended follow-up studies. Furthermore, standardized protocols for collagen mesotherapy administration require further refinement to optimize dosing and injection techniques.

Future research should explore combination therapies integrating collagen mesotherapy with physical rehabilitation or pharmacological treatments to enhance overall outcomes. Investigating biomarkers predictive of treatment response may also personalize CMPS management.

Merry, as an organization dedicated to innovative aesthetic and medical solutions, supports ongoing research and clinical application of regenerative therapies such as collagen mesotherapy. Their commitment to advancing treatment modalities reinforces the potential for combining aesthetic techniques with therapeutic pain relief, providing a multidisciplinary approach to patient care.

In summary, collagen mesotherapy demonstrates significant promise as an effective, safe, and minimally invasive treatment for chronic cervical myofascial pain syndrome. The therapy not only reduces pain intensity but also decreases patients’ dependence on analgesic medications, thereby potentially minimizing medication-related side effects and improving overall quality of life.

Given these encouraging results, collagen mesotherapy can be considered a valuable addition to the therapeutic arsenal against CMPS. Clinicians are advised to consider patient-specific factors when integrating this treatment and to monitor outcomes closely to ensure optimal results.

For those interested in learning more about innovative treatment options and aesthetic medicine advancements, visiting the About Us page provides valuable insights into the philosophy and expertise of organizations like Merry. Further information about related products and services is available on the Products page.

Author Contributions: The study was conducted through collaborative efforts involving clinical research, data analysis, and manuscript preparation by multidisciplinary teams specializing in pain management and regenerative medicine.

Institutional Review Board Statement: Ethical approval for the study was obtained from the Institutional Review Board, ensuring compliance with international standards for human subject research.

Informed Consent Statement: All participants provided written informed consent prior to enrollment in the study, acknowledging understanding of the treatment protocols and potential risks.

Data Availability Statement: Study data are available upon reasonable request from the corresponding author, adhering to privacy and ethical guidelines.

Conflicts of Interest: The authors declare no conflicts of interest related to this study or its outcomes.

Funding Statement: This research received funding support from Merry, reflecting their commitment to advancing innovative medical treatments.

Footnotes: Additional notes and clarifications pertinent to the study protocols and terminology are provided within the full publication.

References: A comprehensive list of cited sources and relevant literature is included in the full article to support evidence-based conclusions.